Business Context and Reporting Period
Company: Adial Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 1, 2021
Reporting Period: Event-based report regarding the closing of a private equity offering on June 1, 2021.
Key Financial Metrics
This filing reports on a specific capital raise event rather than periodic financial performance. Key metrics related to the transaction include:
- Proceeds Raised: $1,809,000
- Shares Issued: 603,000 shares of common stock (303,000 to Bespoke Growth Partners, Inc. and 300,000 to Keystone Capital Partners, LLC)
- Price Per Share: $3.00
- Transaction Costs: No broker fees incurred; no warrants issued.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in equity capital and outstanding share count resulting from the closing of the second tranche of a private offering. This transaction followed the effectiveness of a Form S-3 registration statement filed on April 20, 2021.
Guidance, Outlook, and Risks
Management Commentary: The Company closed the second tranche of its private offering pursuant to Securities Purchase Agreements dated March 11, 2021. The investors (Bespoke and Keystone) are accredited investors purchasing securities as an investment in a private placement without general solicitation.
Risks and Contingencies: The securities were issued pursuant to an exemption from registration requirements under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The filing explicitly states it does not constitute an offer to sell or solicitation of an offer to buy in any state where such offer would be unlawful prior to registration or qualification.
Unusual Items: None reported beyond the standard private placement structure.
Investor Verification Checklist
- Verify the total number of outstanding shares post-transaction to assess dilution impact.
- Confirm the use of proceeds ($1,809,000) in subsequent financial statements or press releases.
- Review the relationship between the investors (Bespoke Growth Partners and Keystone Capital Partners) and Company insiders (Chief Strategy Officer and Board Member) for potential conflicts of interest.
- Check the status of the Form S-3 registration statement (File No. 333-255352) referenced in the filing.